Boston Scientific Co. (NYSE:BSX) Shares Sold by Baron Wealth Management LLC

Baron Wealth Management LLC trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX) by 5.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 3,540 shares of the medical equipment provider’s stock after selling 200 shares during the period. Baron Wealth Management LLC’s holdings in Boston Scientific were worth $316,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Values First Advisors Inc. purchased a new stake in Boston Scientific during the third quarter worth $28,000. Dunhill Financial LLC raised its stake in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 152 shares during the last quarter. Global Wealth Strategies & Associates boosted its position in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new position in Boston Scientific during the fourth quarter worth about $29,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new position in Boston Scientific during the third quarter worth about $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BSX. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Bank of America upped their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Morgan Stanley boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. Wells Fargo & Company raised their price target on shares of Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $97.26.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock valued at $2,702,261 in the last ninety days. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.5 %

NYSE BSX opened at $102.79 on Thursday. The company’s fifty day simple moving average is $92.74 and its 200-day simple moving average is $85.81. The stock has a market cap of $151.50 billion, a P/E ratio of 84.95, a PEG ratio of 2.63 and a beta of 0.80. Boston Scientific Co. has a 52 week low of $61.08 and a 52 week high of $103.17. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.